Anastrozole/Arimidex CAS120511-73-1 99% Purity Anastrozole Arimidex for bodybuilding

Anastrozole/Arimidex CAS120511-73-1 99% Purity Anastrozole Arimidex for bodybuilding

Detalles Rápidos:

Anastrozol
As: Anastrozol,Arimidex,Armotraz,Anastrol,Egistrozol,Anastrozolo
Pureza : 99%min
Número de registro CAS: 120511-73-1
EINECS No: 233-894-8
Fórmula molecular: C17H19N5
Peso molecular:293.37
Calificación : As
Almacenamiento: Sombreado, conservación confinada
Uso : material farmacéutico, etc.

Product description:

Anastrozole Is a non-steroidal drug used to treat breast cancer. In five to eight decades of life, breast cancer women have been thoroughly studied. Some breast cancer depends on the growth of estrogen. Arimidex works by inhibiting the level of estrogen in the body, thereby reducing the growth of breast cancer. Although taking tamoxifen, the drug is a first-line treatment for postmenopausal women with early breast cancer or advanced breast cancer. Arimidex is usually combined with other drugs for the treatment of postmenopausal women with breast cancer. The drug has been used to treat women in all cultures and races of early or late breast cancer.

Anastrozole Is the first generation of third generation aromatase inhibitors, can be used for the second line in 1995 treatment of advanced breast cancer.

Aromatic enzymes belong to the group of cytochrome P450 enzymes involved in steroid biosynthesis. Found in peripheral tissues, including muscle, fat and liver as well as breast tumor cells.

Aromatherapy is the last step in the synthesis of estrogen, the androgen androstenedione and testosterone into estrogen and estradiol estradiol. Aromatase inhibitors act by blocking this transformation, thereby reducing the availability of circulating estrogens. The inhibition of estrogen production is an effective treatment for women with hormone-dependent breast cancer. Aromatase inhibitors have been developed for postmenopausal women, in which estrogen is mainly synthesized by the conversion of adrenergic steroids androstenedione to estrogen.

Arimidex is reversibly bound to aromatase and classified as type II nonsteroidal aromatase inhibitors. In premenopausal women, ovaries are a major part of estrogen production. Because aromatase inhibitors can not completely block ovarian estrogen synthesis, it can not be used as the only endocrine therapy for premenopausal patients. In this patient group, sin embargo, the aromase inhibitor may be used in combination with a drug that inhibits ovarian function, such as goserelin, a gonadotropin releasing hormone agonist. Sin embargo, only limited data is available to support this combination.

The report of product quality analysis: